J. Himmelfarb et L. Couper, DIPYRIDAMOLE INHIBITS PDGF-INDUCED AND BFGF-INDUCED VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION, Kidney international, 52(6), 1997, pp. 1671-1677
Dipyridamole is the only pharmacologic agent demonstrated to reduce po
lytetrafluoroethylene (PTFE) graft occlusion in hemodialysis patients.
However, the mechanism of action of dipyridamole in preventing graft
occlusion is unknown. The purpose of this study was to examine the dir
ect effects of dipyridamole on both platelet-derived growth factor (PD
GF) and basic fibroblast growth factor (bFGF)-induced vascular smooth
muscle cell (VSMC) proliferation. Human aortic smooth muscle cells wer
e grown to confluence in 96 well plates. A total of 5 x 10(-6) molar d
ipyridamole, PDGF 10 ng/ml, or bFGF 10 ng/ml were added to appropriate
wells at the start of each experiment. Cell proliferation at 48 hours
was determined using tritiated thymidine uptake. Intracellular cyclic
AMP (cAMP) was measured using a competitive enzyme immunoassay. Treat
ment of VSMC with 5 mu M dipyridamole dramatically reduced basal proli
feration rates compared to controls [5229 +/- 1131 counts per minute (
CPM) versus 387 +/- 68 CPM, P < 0.001]. Treatment with dipyridamole al
so reduced PDGF-stimulated VSMC proliferation (7311 +/- 1655 CPM vs. 5
93 +/- 110 CPM, P < 0.001) as well as the response to bFGF (5632 +/- 1
270 CPM vs. 310 +/- 31 CPM, P < 0.001). Treatment of VSMC with either
5 or 20 mu M dipyridamole did not change intracellular cAMP levels. Fu
rthermore, the addition of dibutyryl cAMP to VSMC demonstrated only a
modest inhibitory effect on proliferation. We conclude that dipyridamo
le inhibits both PDGF- and bFGF-stimulated VSMC proliferation. The eff
ects of dipyridamole on VSMC proliferation do not appear to be entirel
y mediated by changes in intracellular cAMP concentrations. The direct
effect of dipyridamole on VSMC proliferation may account for its effi
cacy in reducing PTFE graft thrombosis in hemodialysis patients.